Advertisement
New Zealand markets close in 1 hour 12 minutes

  • NZX 50

    11,737.14
    -98.90 (-0.84%)
     

  • NZD/USD

    0.5879
    -0.0027 (-0.46%)
     

  • NZD/EUR

    0.5524
    -0.0021 (-0.37%)
     

  • ALL ORDS

    7,786.40
    -112.50 (-1.42%)
     

  • ASX 200

    7,537.30
    -104.80 (-1.37%)
     

  • OIL

    84.71
    +1.98 (+2.39%)
     

  • GOLD

    2,405.00
    +7.00 (+0.29%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,160.76
    -225.11 (-1.37%)
     

  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

  • NZD/JPY

    90.6450
    -0.6090 (-0.67%)
     

AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

AIM ImmunoTech Inc.
·1-min read

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET

OCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 10:00 AM ET.

As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

ADVERTISEMENT

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

For more information, please visit www.aimimmuno.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com